Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Moodys
Boehringer Ingelheim
AstraZeneca
Baxter

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEMADEX

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Demadex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00602303 Bioequivalency Study of Torsemide Tablets Under Fasting Conditions Completed Roxane Laboratories N/A 2003-09-01 The objective of this study was the bioequivalence of a Roxane Laboratories' Torsemide Tablets, 20 mg, to Demadex® Tablets, 20 mg (Roche) under fasting conditions using a single-dose, 2-treatment, 2-period, crossover design.
NCT00602615 Bioequivalency Study of Torsemide Tablets Under Fed Conditions Completed Roxane Laboratories N/A 2003-09-01 The objective of this study was the bioequivalence of a Roxane Laboratories' Torsemide Tablets, 20 mg, to Demadex® Tablets, 20 mg (Roche) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.
NCT00653549 Bioavailability Study of Torsemide Tablets Under Fasting Conditions Completed Anapharm Phase 1 2001-04-01 To compare the single-dose bioavailability of Torsemide tablets with Demadex
NCT00653549 Bioavailability Study of Torsemide Tablets Under Fasting Conditions Completed Par Pharmaceutical, Inc. Phase 1 2001-04-01 To compare the single-dose bioavailability of Torsemide tablets with Demadex
NCT00654043 Bioavailability Study of Torsemide Tablets Under Fed Conditions Completed Anapharm Phase 1 2001-04-01 To compare the single-dose bioavailability of Torsemide tablets with Demadex
NCT00654043 Bioavailability Study of Torsemide Tablets Under Fed Conditions Completed Par Pharmaceutical, Inc. Phase 1 2001-04-01 To compare the single-dose bioavailability of Torsemide tablets with Demadex
NCT03187509 Weight-Based Torsemide Dosing in Subjects With Heart Failure Not yet recruiting New York City Health and Hospitals Corporation N/A 2018-01-01 This study will be a randomized open-label pilot study. The purpose of the study is to compare standard of care outpatient heart failure management versus a weight based torsemide regimen. Subjects admitted to the hospital for heart failure exacerbation will be randomized upon discharge to either standard of care outpatient heart failure management or a weight based torsemide regimen. Those subjects randomized to standard of care therapy will be prescribed a daily fixed dose of a loop diuretic at hospital discharge and have a follow-up appointment within one week of discharge. All management decisions including loop diuretic type, dose and frequency will be made at the discretion of the subject's personal physician. Those randomized to an individualized weight based torsemide regimen will be prescribed a dose of torsemide upon hospital discharge based on a prespecified algorithm. These subjects will then undergo physician-subject phone encounters three times a week where the subject's torsemide dose will be modified based on the prespecified algorithm which incorporates current symptoms and weight. Primary end-point will be an unbiased estimate of 30-day all cause readmission rates. Secondary end-points include incidence of acute kidney injury, changes in brain natriuretic peptide levels from baseline and a preliminary estimate of the effect size and feasibility of a weight-based torsemide regimen intervention in order to plan a future larger study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Demadex

Condition Name

Condition Name for Demadex
Intervention Trials
Edema 2
Heart Failure 1
Healthy 1
Congestive Heart Failure 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Demadex
Intervention Trials
Heart Failure 2
Disease 1
Body Weight Changes 1
Body Weight 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Demadex

Trials by Country

Trials by Country for Demadex
Location Trials
United States 2
India 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Demadex
Location Trials
Missouri 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Demadex

Clinical Trial Phase

Clinical Trial Phase for Demadex
Clinical Trial Phase Trials
Phase 1 4
N/A 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Demadex
Clinical Trial Phase Trials
Completed 4
Not yet recruiting 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Demadex

Sponsor Name

Sponsor Name for Demadex
Sponsor Trials
Roxane Laboratories 2
Sarfez Pharmaceuticals, Inc. 2
Par Pharmaceutical, Inc. 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Demadex
Sponsor Trials
Industry 8
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
AstraZeneca
Moodys
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.